Jan 1, 2009
By:
Jill Wechsler
Will more resourches and new leadership fix FDA, or is a major overhaul in order?
|
Dec 1, 2008
By:
Jill Wechsler
To expand health coverage amid an economic crisis, Obama will be looking hard for ways to cut costs
|
Financial links to biomedical researchers may lead to stiffer disclosure rules for pharma and challenges for research partnerships
Nov 1, 2008
By:
Jill Wechsler
As Congress moves to curb industry influence, support for med ed is waning
|
Oct 1, 2008
By:
Jill Wechsler
Congressional leaders ready campaign to curb Medicare drug plans.
|
Sep 1, 2008
By:
Jill Wechsler
FDA missteps and global outsourcing are drawing Congressional scrutiny and prompting new oversight approaches
|
Aug 1, 2008
By:
Jill Wechsler
FDA's new sentinel system shows the pendulum swing toward safety won't swing back anytime soon
|
Rare disease treatments are riding high as patient advocates, pharma companies, and government officials celebrate the ODA's 25th anniversary
Jul 1, 2008
By:
Jill Wechsler
Rare disease treatments are riding high as patient adcovates, pharma companies, and government officials celebrate the ODA's 25th anniversary
|
Jun 1, 2008
By:
Jill Wechsler
US presidential hopefuls look to comparative effectiveness analysis to address price and access issues
|
May 21, 2008
By:
Jill Wechsler
Feds consider adding an 800 number to television ads for adverse event reporting. Does this shine light on DTC ads while pushing public health goals? Industry is mum on the topic
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
